Subscribe free

Cytoreductive Surgery & Peritoneum ·

Long-term Survival in Patients with Colorectal Peritoneal Carcinomatosis Treated with CRS/HIPEC

Actual 5-year survival rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for patients with peritoneal carcinomatosis (PC) of colorectal origin were reported in this study. A total of 103 patients were analyzed, with a median follow-up of survivors at 88 months. The 5-year overall survival (OS) was 36%, and the median OS was 42.5 months. Factors associated with poor survival included high peritoneal cancer index (PCI) and incomplete CRS. However, patients with low PCI who underwent complete surgical resection achieved favorable long-term survival with a 5-year OS of 60.7%.

Journal Article by Sarfaty E, Khajoueinejad N (…) Cohen NA et 5 al. in Ann Surg Oncol

© 2023. Society of Surgical Oncology.

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →